Caris Life Sciences (CAI) Preferred Dividend Payments (2024 - 2025)
Caris Life Sciences' (CAI) quarterly Preferred Dividend Payments came in at $61.0 million in Q2 2025, up 149.25% quarter-over-quarter from $24.5 million in Q1 2025.
Caris Life Sciences (CAI) Preferred Dividend Payments (2024 - 2025) Analysis & Trends
Caris Life Sciences' Preferred Dividend Payments history runs 2 years deep, the most recent figure standing at $61.0 million for Q2 2025.
- On a quarterly basis, Preferred Dividend Payments changed N/A year-over-year to $61.0 million in Q2 2025; TTM through Mar 2026 was $61.0 million, a 49.54% decrease from a year earlier, with the FY2025 full-year figure at $85.4 million, down 11.35% from the prior year.
- Preferred Dividend Payments climbed to $61.0 million in Q2 2025 per CAI's latest filing, from $24.5 million in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $96.4 million in Q4 2024 and bottomed at $24.5 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Caris Life Sciences | 4.35 Bn | 3.53 Bn | 214.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 60.97 Mn |
| Mar 31, 2025 | 24.46 Mn |
| Dec 31, 2024 | 96.37 Mn |